Tags

Type your tag names separated by a space and hit enter

3,4 Methylenedioxymethamphetamine-induced conditioned place preference (CPP) is mediated by endocannabinoid system.
Pharmacol Res. 2005 Feb; 51(2):177-82.PR

Abstract

The appetitive potential of i.c.v. injections of 3,4 methylenedioxymethamphetamine (MDMA), using a conditioned place preference (CPP) procedure, was investigated. In a range of doses (0.1-10 ng/rat), devoid of motor stimulation, a dose-dependent CPP was obtained. The effect of the most effective dose (10 ng/rat) was prevented by pre-treatment with the CB1 cannabinoid (SR 141716A) [N-piperidino-5-(4-chlorophenyl) 1-(2, 4-dichloro-phenyl)-4-methyl pyrazole-3-carboxamide hydrochloride] (0.5 mg kg(-1)), the opioid (naloxone) (2 mg kg(-1)), and the serotonin 5-HT3, tropisetron [endo-8-methyl-8-azabicyclo [3.2.1] oct-3-olindol-3-yl-carboxylate hydrochloride] (1 mg kg(-1)), receptor antagonists, which did not induce place conditioning on their own. SR 141716A was more efficient than naloxone and tropisetron in blocking the incentive learning supported by MDMA. These results demonstrate for the first time that i.c.v. MDMA, at very low doses, induces CPP and that endocannabinoid system may participate in this effect.

Authors+Show Affiliations

Department of Pharmacology, Chemotherapy and Medical Toxicology, Faculty of Sciences, University of Milan, Via Vanvitelli 32, 20129 Milan, Italy.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15629265

Citation

Braida, D, et al. "3,4 Methylenedioxymethamphetamine-induced Conditioned Place Preference (CPP) Is Mediated By Endocannabinoid System." Pharmacological Research, vol. 51, no. 2, 2005, pp. 177-82.
Braida D, Iosuè S, Pegorini S, et al. 3,4 Methylenedioxymethamphetamine-induced conditioned place preference (CPP) is mediated by endocannabinoid system. Pharmacol Res. 2005;51(2):177-82.
Braida, D., Iosuè, S., Pegorini, S., & Sala, M. (2005). 3,4 Methylenedioxymethamphetamine-induced conditioned place preference (CPP) is mediated by endocannabinoid system. Pharmacological Research, 51(2), 177-82.
Braida D, et al. 3,4 Methylenedioxymethamphetamine-induced Conditioned Place Preference (CPP) Is Mediated By Endocannabinoid System. Pharmacol Res. 2005;51(2):177-82. PubMed PMID: 15629265.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - 3,4 Methylenedioxymethamphetamine-induced conditioned place preference (CPP) is mediated by endocannabinoid system. AU - Braida,D, AU - Iosuè,S, AU - Pegorini,S, AU - Sala,M, PY - 2004/07/21/accepted PY - 2005/1/5/pubmed PY - 2005/6/4/medline PY - 2005/1/5/entrez SP - 177 EP - 82 JF - Pharmacological research JO - Pharmacol. Res. VL - 51 IS - 2 N2 - The appetitive potential of i.c.v. injections of 3,4 methylenedioxymethamphetamine (MDMA), using a conditioned place preference (CPP) procedure, was investigated. In a range of doses (0.1-10 ng/rat), devoid of motor stimulation, a dose-dependent CPP was obtained. The effect of the most effective dose (10 ng/rat) was prevented by pre-treatment with the CB1 cannabinoid (SR 141716A) [N-piperidino-5-(4-chlorophenyl) 1-(2, 4-dichloro-phenyl)-4-methyl pyrazole-3-carboxamide hydrochloride] (0.5 mg kg(-1)), the opioid (naloxone) (2 mg kg(-1)), and the serotonin 5-HT3, tropisetron [endo-8-methyl-8-azabicyclo [3.2.1] oct-3-olindol-3-yl-carboxylate hydrochloride] (1 mg kg(-1)), receptor antagonists, which did not induce place conditioning on their own. SR 141716A was more efficient than naloxone and tropisetron in blocking the incentive learning supported by MDMA. These results demonstrate for the first time that i.c.v. MDMA, at very low doses, induces CPP and that endocannabinoid system may participate in this effect. SN - 1043-6618 UR - https://www.unboundmedicine.com/medline/citation/15629265/34_Methylenedioxymethamphetamine_induced_conditioned_place_preference__CPP__is_mediated_by_endocannabinoid_system_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1043-6618(04)00191-4 DB - PRIME DP - Unbound Medicine ER -